Ingevity Corp (NGVT) · Nov 4, 2026 · Earnings

Ingevity earnings beat as 2026 guidance tightens, APT sale slips

Beat — Diluted adjusted EPS $1.63 vs ~$1.56 consensus

Ingevity earnings modestly beat Q3 expectations and tightened 2026 EBITDA guidance, but weaker free cash flow and a delayed APT sale temper the read.

Ingevity is midway through a portfolio simplification: Performance Materials is the core earnings engine, while Pavement Technologies is under pressure and Advanced Polymer Technologies is being prepared for a potential sale. The company had been targeting a year-end 2026 strategic outcome for APT, making the timing update relevant even though the broader direction was already known.

The quarter modestly beat the operating bar. Diluted adjusted EPS was $1.63 versus a published consensus of roughly $1.56, while revenue of $305.1 million was slightly above the roughly $303.9 million expectation. The beat came with mixed underlying demand: Performance Materials held EBITDA essentially flat despite softer automotive volumes overseas, Advanced Polymer Technologies improved, but Pavement Technologies EBITDA fell sharply as demand and input costs weighed.

Q3 2026Q3 2025Consensus
Net sales (Financial Highlights)$305.1M (+0.5%)$333.1M$303.9M
Diluted adjusted EPS (Adjusted EPS reconciliation)$1.63 (+24.4%)$1.31~$1.56
Adjusted EBITDA (Adjusted EBITDA reconciliation)$108.0M (-2.2%)$110.4M
Free cash flow (Free Cash Flow Calculation)$85.5M (-27.4%)$117.8M

The guidance change is better than a simple reaffirmation, but not a major reset. Full-year adjusted EBITDA is now narrowed to $385 million-$395 million from $380 million-$400 million, lifting the midpoint from $390 million to $390 million while reducing the range of outcomes. The adjusted EPS range also moves up at the low end to $5.25-$5.45 from $5.00-$5.45, implying better visibility rather than a higher top-end ambition. The company’s prior outlook had included the same broad EBITDA framework and full-year APT results.

The cash-flow picture is less clean. Third-quarter free cash flow fell to $85.5 million, and the new full-year range of $220 million-$230 million trims the prior $220 million-$245 million range, reflecting higher capital spending and working-capital investment. That matters because deleveraging and shareholder returns are central to the post-restructuring story, even though net leverage remained at 2.5x and below the prior-year 2.7x.

The APT strategic catalyst is pushed out, not removed. Management said an announced agreement may extend into early 2027 rather than arrive within 2026. That is a timing setback for the portfolio simplification plan, but it does not change the stated intention to pursue a sale; meanwhile, APT’s quarterly revenue rose 18% and EBITDA improved modestly, giving the business a better operating profile while it remains in the portfolio. 〔0〕

Bottom line: This is a modestly better quarter with tighter, slightly improved earnings visibility, but lower cash-flow guidance and a delayed APT sale keep it from being a clean upgrade to the story.

What to watch next

APT sale agreement, potentially early 2027

Original filing on SEC EDGAR

Ingevity earnings beat as 2026 guidance tightens, APT sale slips | NGVT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.